Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma

Next Previous
Drug Profile

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma

Alternative Names: AMG-827; KHK-4827; Kyntheum; LP 0160; LUMICEF; SILIQ; Siliq

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bausch Health Companies; Kyowa Hakko Kirin; Kyowa Kirin; LEO Pharma
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Axial spondyloarthritis; Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Preregistration Systemic scleroderma
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 30 Jun 2025 Registered for Palmoplantar pustulosis in Taiwan (SC), before June 2025 (Kyowa Kirin pipeline, August 2025)
  • 11 Apr 2025 Kyowa Kirin completes a phase-III trial in Systemic scleroderma in Japan (NCT03957681)
  • 31 Mar 2025 Kyowa Kirin completes a phase-I trial in Systemic scleroderma in Japan (NCT04368403), (JapicCTI173686)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top